SNY (Sanofi) Prakiraan wutah bathi resik saben saham ing taun iki

SNY (Sanofi Group) - tandha merek perusahaan

Despite stable commercial momentum and steady cash inflows, the shift in earnings per share compared to last year demonstrates capital recovery dynamics, with the latest value recorded as 6.40. The internal strength of Sanofi relies on the demand for vaccines and drugs for rare pathologies. The holding's revenues are based on the sale of prescription drugs for the therapy of diabetes, cardiovascular, and immunological disorders.

SNY - Wutah bathi ing taun lumaku Sanofi S.A. ing rentang 04.07.2022 - 15.11.2026

Rincian metrik keuangan lan pasar sanofi.com (SNY)

- kuotasi lan prakiraan analis:
Kurs saham Sanofi Aventis|SNY - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Sanofi S.A.|SNY - Nilai Total Perusahaan
- data nilai buku modal saham:
Ekuitas saben Saham Sanofi|SNY - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas sanofi.com|SNY - Aset Agregat Perusahaan
- rincian utang lan likuiditas:
Koefisien Total Utang marang Modal Sanofi|SNY - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Sanofi SA|SNY - Utang perusahaan|Rasio utang marang nilai buku Sanofi S.A.|SNY - Utang jangka dawa perusahaan|Utang jangka cendhak Sanofi|Rasio likuiditas kritis sanofi.com
- statistik bathi lan rasio pasar:
SNY - Bathi resik|Prakiraan bathi perusahaan Sanofi|SNY - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi sanofi.com|SNY - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Sanofi SA|SNY - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Sanofi|SNY - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan sanofi.com|SNY - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Sanofi
- informasi babagan volume dodolan lan pendapatan:
SNY - Pendapatan lan volume dodolan|Prakiraan volume dodolan Sanofi Group|SNY - Rasio rega marang pendapatan|Rega forward marang dodolan Sanofi S.A.
Analisis dhasar perusahaan:Sanofi Group
Produk seri Sanofi

The efficiency of the global manufacturing network of Sanofi (SNY) and the stability of drug production are reflected in the annual net income per share trend, demonstrating the actual profitability of the business. This indicator measures EPS growth rates relative to the previous year, revealing the company's ability to pass inflationary costs onto consumers; a fading of this trend signals declining demand and the risk of capital freezing.

Pesaing utama

Wutah bathi saben saham ing taun iki LLY|ABBV (AbbVie) - Wutah bathi ing taun lumaku|astrazeneca.com (AZN) - Prakiraan wutah bathi resik saben saham ing taun iki|Wutah bathi saben saham ing taun lumaku Novartis Inc. (NVS)|Merck - Wutah bathi saben saham ing taun iki|Wutah bathi ing taun lumaku NVO (Novo Nordisk AS)|AMGN: Wutah bathi saben saham ing taun iki|PFE - Wutah bathi saben saham ing taun lumaku|BMY: Wutah bathi saben saham ing taun lumaku|GSK plc (GSK) - Wutah bathi saben saham ing taun lumaku|Takeda Pharmaceutical Company (TAK) - Wutah bathi ing taun lumaku|TEVA (tevapharm.com) - Wutah bathi ing taun lumaku|Dr. Reddy's Laboratories (RDY) - Prakiraan wutah bathi resik saben saham ing taun iki|Wutah bathi ing taun lumaku VTRS|Prakiraan wutah bathi resik saben saham ing taun iki Roivant Sciences|Zai Lab - Wutah bathi resik saben saham ing taun iki|BHC - Wutah bathi resik saben saham ing taun iki|COSM - Wutah bathi saben saham ing taun lumaku